Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px
Document › Details

Gimv. (5/2/17). "Press Release: Gimv Invests in Emerging Immuno-oncology Company ImCheck Therapeutics". Antwerp & Marseille.

Organisations Organisation Gimv Health & Care fund
  Group Gimv (Group)
  Organisation 2 ImCheck Therapeutics S.A.S.
Products Product immunotherapy
  Product 2 venture capital
Index terms Index term ImCheck Therapeutics–SEVERAL: investment, 201705 financing round Series A €20m from BIVF + Kurma Partners + Idinvest + Gimv + LSP
  Index term 2 ImCheck Therapeutics–Gimv: investment, 201705 financing round Series A totalling €20m incl co-investor Gimv
Person Person De Leenheer, Frank (Gimv 201509 IR + Corporate Communications Manager)

Gimv today announces a EUR 5 million investment in French ImCheck Therapeutics, an emerging player in the field of cancer and auto-immune immunotherapies that focuses on the development of first-in-class antibodies that activate the immune system against different cancer types. This investment is part of a total Series A financing of EUR 20 million from a consortium of specialized life sciences investors including Kurma, Boehringer Ingelheim Venture Fund (BIVF), Idinvest and Life Science Partners (LSP).

ImCheck Therapeutics was founded in 2015 as a spin-off from the Paoli-Calmettes Cancer Institute in Marseille (France). The company is developing innovative antibody therapeutics in the field of immuno-oncology, based on scientific assets originating from the pioneering work of Prof. Daniel Olive. The funds will be used to advance its lead candidates towards clinical development, as well as to progress its discovery programs.

Karl Nägler, Partner in Gimv’s Health and Care platform, on this transaction: «We are excited to partner with ImCheck and with such a strong syndicate of first class biotech investors, given the game-changing potential of ImCheck’s development candidates for the treatment of cancer. After earlier investments in Topas Therapeutics, G-Therapeutics, Endostim, Spineart and Breath Therapeutics, ImCheck Therapeutics in the sixth new investment of Gimv’s Health & Care team over the past 12 months.»

For further information, we refer to the company’s press release in attachment.


Gimv is a European investment company with over three decades experience in private equity and venture capital. The company is listed on Euronext Brussels. Gimv currently manages around 1.8 billion EUR (including co-investment partnerships) of investments in about 50 portfolio companies.

As a recognized market leader in selected investment platforms, Gimv identifies entrepreneurial and innovative companies with high-growth potential and supports them in their transformation into market leaders. Gimv’s four investment platforms are: Connected Consumer, Health & Care, Smart Industries and Sustainable Cities. Each of these platforms works with a skilled and dedicated team across Gimv’s home markets of the Benelux, France and Germany and can count on an extended international network of experts.

More information on Gimv can be found on

For further information please contact:

Karl Nägler, Partner Health & Care Gimv
T +49 89 44 23 27 50 –

Frank De Leenheer, Investor Relations & Corporate Communications Manager Gimv
T +32 3 290 22 18 –

Gimv NV - Karel Oomsstraat 37, 2018 Antwerp, Belgium - T +32 3 290 21 00 - F +32 3 290 21 05 -

Record changed: 2017-05-07


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Gimv (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top